PMID- 28517532
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 2473-4209 (Electronic)
IS  - 0094-2405 (Linking)
VI  - 39
IP  - 6Part20
DP  - 2012 Jun
TI  - SU-E-T-646: Feasibility Study of Proton Arc Therapy for the Treatment of 
      Para-Aortic Lymph Node Tumor.
PG  - 3854
LID - 10.1118/1.4735735 [doi]
AB  - PURPOSE: To test feasibility of proton arc therapy (PAT) in the treatment of 
      para-aortic lymph node tumor and compare its dosimetric properties with advanced 
      radiotherapy techniques such as intensity modulated radiation therapy (IMRT) and 
      conventional 3D conformal proton beam therapy (PBT). METHODS: The treatment plans 
      for para-aortic lymph node tumor were planned for 9 patients treated at our 
      institution using IMRT, PBT, and PAT. Feasibility test and dosimetric evaluation 
      were based on comparisons of dose volume histograms (DVHs) which reveal mean 
      dose, D30%, D60%, D90%, V30%, V60%, V90%, organ equivalent doses (OEDs), normal 
      tissue complication probability (NTCP), homogeneity index (HI) and conformity 
      index (CI). RESULTS: The average doses delivered by PAT to the liver, kidney, 
      small bowel, duodenum, stomach were 7.6%, 3%, 17.3%, 26.7%, and 14.4%, of the 
      prescription dose (PD), respectively, which is higher than the doses delivered by 
      IMRT (0.4%, 7.2%, 14.2%, 15.9%, and 12.8%, respectively) and PBT (4.9%, 0.5%, 
      14.12%, 16.1% 9.9%, respectively). The average homogeneity index and conformity 
      index of tumor using PAT were 12.1 and 1.21, respectively which were much better 
      than IMRT (21.5 and 1.47, respectively) and comparable to PBT (13.1 and 1.23, 
      respectively). The Result shows that both NTCP and OED of PAT are generally lower 
      than IMRT and PBT. CONCLUSIONS: This study demonstrates that PAT is better in 
      target conformity and homogeneity than IMRT and PBT but worse than IMRT and PBT 
      for most of dosimetric factor which indicate that PAT is not recommended for the 
      treatment of para-aortic lymph node tumor.
CI  - (c) 2012 American Association of Physicists in Medicine.
FAU - Kim, J
AU  - Kim J
AD  - Myongji hospital, Goyang-si, gyeonggi-do.
AD  - Yonsei University Wonju, WOUNJU.
AD  - National Cancer Center, Goyang-si, Gyeonggi.
FAU - Rah, J
AU  - Rah J
AD  - Myongji hospital, Goyang-si, gyeonggi-do.
AD  - Yonsei University Wonju, WOUNJU.
AD  - National Cancer Center, Goyang-si, Gyeonggi.
FAU - Yoon, M
AU  - Yoon M
AD  - Myongji hospital, Goyang-si, gyeonggi-do.
AD  - Yonsei University Wonju, WOUNJU.
AD  - National Cancer Center, Goyang-si, Gyeonggi.
FAU - Shin, D
AU  - Shin D
AD  - Myongji hospital, Goyang-si, gyeonggi-do.
AD  - Yonsei University Wonju, WOUNJU.
AD  - National Cancer Center, Goyang-si, Gyeonggi.
FAU - Kim, D
AU  - Kim D
AD  - Myongji hospital, Goyang-si, gyeonggi-do.
AD  - Yonsei University Wonju, WOUNJU.
AD  - National Cancer Center, Goyang-si, Gyeonggi.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Phys
JT  - Medical physics
JID - 0425746
OTO - NOTNLM
OT  - Anatomy
OT  - Cancer
OT  - Conformal radiation therapy
OT  - Dosimetry
OT  - Intensity modulated radiation therapy
OT  - Photoacoustic imaging
OT  - Proton therapy
OT  - Radiation therapy
OT  - Radiation treatment
OT  - Therapeutics
EDAT- 2012/06/01 00:00
MHDA- 2012/06/01 00:01
CRDT- 2017/05/19 06:00
PHST- 2017/05/19 06:00 [entrez]
PHST- 2012/06/01 00:00 [pubmed]
PHST- 2012/06/01 00:01 [medline]
AID - 10.1118/1.4735735 [doi]
PST - ppublish
SO  - Med Phys. 2012 Jun;39(6Part20):3854. doi: 10.1118/1.4735735.